9 research outputs found
Characteristics of study paticipants according to clinical presentation.
<p>Characteristics of study paticipants according to clinical presentation.</p
Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma
<div><p>Background</p><p>Circulating microRNAs (miRNA) are biomarkers for several neoplastic diseases, including hepatocellular carcinoma (HCC). We performed a literature search, followed by experimental screening and validation in order to establish a miRNA panel in combination with the assessment of alpha-fetoprotein (AFP) levels and to evaluate its performance in HCC diagnostics.</p><p>Methods</p><p>Expression of miRNAs was quantified by quantitative PCR (qPCR) in 406 serum samples from 118 Vietnamese patients with hepatitis B (HBV)-related HCC, 69 patients with HBV-related liver cirrhosis (LC), 100 chronic hepatitis B (CHB) patients and 119 healthy controls (HC).</p><p>Results</p><p>Three miRNAs (mir-21, mir-122, mir-192) were expressed differentially among the studied subgroups and positively correlated with AFP levels. The individual miRNAs mir-21, mir-122, mir192 or the triplex miRNA panel showed high diagnostic accuracy for HCC (HCC vs. CHB, AUC = 0.906; HCC vs. CHB+LC, AUC = 0.81; HCC vs. CHB+LC+HC, AUC = 0.854). When AFP levels were ≤20ng/ml, the triplex miRNA panel still was accurate in distinguishing HCC from the other conditions (CHB, AUC = 0.922; CHB+LC, AUC = 0.836; CHB+LC+HC, AUC = 0.862). When AFP levels were used in combination with the triplex miRNA panel, the diagnostic performance was significantly improved in discriminating HCC from the other groups (LC, AUC = 0.887; CHB, AUC = 0.948; CHB+LC, AUC = 0.887).</p><p>Conclusions</p><p>The three miRNAs mir-21, mir-122, mir-192, together with AFP, are biomarkers that may be applied to improve diagnostics of HCC in HBV patients, especially in HBV-related LC patients with normal AFP levels or HCC patients with small tumor sizes.</p></div
Differential expression miRNAs and AFP levels in different groups.
<p>Differential expression of miR-21 (A), miR-122 (B) and miR-192 (C) and alpha-fetoprotein (D) in different groups of HBV-related liver diseases including hepatocellular carcinoma (HCC), liver cirrhosis (LC), chronic hepatitis B (CHB) and healthy controls (HC). Numbers in brackets = n of individuals tested. <i>P</i> values were calculated by non-parametric Mann-Whitney U-test for pair-wise comparisons between groups.</p
Diagnostic performance of miRNA panels in combination with alpha-fetoprotein in differentiating HCC against control subjects.
<p>Diagnostic performance of miRNA panels in combination with alpha-fetoprotein in differentiating HCC against control subjects.</p
Diagnostics performance of triplex miRNA panel in patients with normal AFP level.
<p>Diagnostic performance of the panel Mir@AFP based on the miRNAs miR-21, miR-122, miR-192 and AFP in differentiating hepatocellular carcinoma with normal AFP levels from other conditions (<20 ng/l). (A): HCC vs. CHB; (B): HCC vs. LC; (C): HCC vs. LC+CHB and (D): HCC vs. (LC+CHB+HC).</p
Diagnostics performance of miRNA panels and in combination with AFP levels.
<p>Diagnostic performance of the triplex miRNA panel based on the miRNAs miR-21, miR-122 and miR-192 levels in differentiating hepatocellular carcinoma from other conditions. (A): HCC vs. CHB; (B): HCC vs. LC; (C): HCC vs. LC+CHB and (D): HCC vs. (LC+CHB+HC).</p
Characteristics of study paticipants according to clinical presentation.
<p>Characteristics of study paticipants according to clinical presentation.</p
Study design.
<p>miRNAs described in studies with more than 100 HCC patients were considered for screening in eight HCC and eight CHB serum samples. Only miRNAs differentially expressed at least twice were selected for further validation.</p